Other · developed by Sanofi
Brivekimig (SAR442970) is administered subcutaneously.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06975722 | Phase 2 | Ulcerative Colitis | Active not recruiting | SNY |
| NCT06500702 | Phase 2 | Focal Segmental Glomerulosclerosis | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal LesionUlcerative Colitis
Updated Nov 22, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →